CD133: A cancer stem cells marker, is used in colorectal cancers

Table 1 Studies of the relationship between CD133 expression and survival

Ref.	n	Cancer category	Tumor stage	Method	Did CD133 expression predict poor survival?
Choi et al[34]	523	Colorectal adenocarcinomas	Stages I-IV	IHC	No: overall survival
Kemper et al[51]	90	Colorectal cancers	Stage II	RT-PCR	Yes: relapse-free survival
Saigusa et al[55]	52	Rectal cancers (post-CRT)	Unclear	RT-PCR	Yes: recurrence-free survival
Jao et al[57]	233	Colorectal adenocarcinomas (post-CRT)	Stages I-IV	IHC	Yes: overall survival
Saigusa et al[59]	33	Rectal cancers (post-CRT)	Stage II/III	RT-PCR	Yes: disease-free survival
Horst et al[60]	77	Colorectal adenocarcinomas	T2/T3, N0, M0	IHC	Yes: cancer-specific survival
Yasuda et al[65]	40	Rectal cancers (post-CRT)	Advanced	RT-PCR	Yes: disease-free survival
Li et al[66]	104	Colon carcinomas	Stage IIIB	IHC	Yes: overall survival
Artells et al[67]	60	Colorectal cancers	Stages I-III	RT-PCR	Yes: overall survival
Kojima et al[69]	160	Colorectal cancers	Stages I-IV (well- and moderately-differentiated)	IHC	Yes: overall survival
Kojima et al[69]	140	Colorectal cancers	Stages I-IV (well- and moderately-differentiated)	IHC	No: recurrence-free survival

IHC: Immunohistochemistry; RT-PCR: Reverse-transcription polymerase chain reaction; CRT: Chemoradiotherapy.